Point-of-care molecular diagnostics instrumentation
Biocartis is a commercial stage company which develops novel molecular diagnostics. The proprietary Idylla™ platform is a fully automated, real-time system which provides accurate, highly-reliable RNA and protein expression information from any biological sample, thus improving diagnosis and facilitating personalised therapy at the point of care.
CEO Rudi Pauwels
Advent Contact Raj Parekh
Advent invested in the Series A in 2009. Biocartis listed on Euronext Brussels in 2015 (EBR:BCART).
Exited Investments
Biocartis raises eur 100 million in successful initial public offering
Press Release. Mechelen, Belgium, 24 April 2015 – Biocartis Group NV (the “Company” or “Biocartis”), an innovative molecular diagnostics company, today announces the results of its initial public offering,…
Read More
Biocartis raises eur 64.5 million (approx. USD 85 million)
Press Release. Investment supports commercial roll-out of Idylla™, Biocartis’ flagship molecular diagnostics system, and the development of the system’s menu of diagnostics tests. Mechelen (Belgium), September 4, 2014…
Read More
Biocartis completes €34,5million ($44,5 million) Series D Fund Raising
Press Release. Capital to be used to commercialize recently launched DMAT platform, validate APOLLO platform and build proprietary oncology content on both platforms. Strong support from internal shareholders and…
Read More
Biocartis announces commercial launch of a new biomarker analysis platform
Press Release. Lausanne, Switzerland – 5 December 2012 Biocartis launches its revolutionary detection platform, Dynamic Multi-Analyte Technology (“DMAT”): New proteomic and nucleic acid platform provides ultra-high quality data analysis…
Read More
Biocartis completes EUR 71 million (USD 100 million) Series C Fund Raising
Press Release. Lausanne (Switzerland) – November 17, 2011. Biocartis, a company developing and commercializing compact molecular diagnostic (MDx) systems designed to drive the widespread adoption of personalized medicine and…
Read More
Biocartis named as a Technology Pioneer 2012 by the World Economic Forum
Press Release. Mechelen, Belgium. 1st September, 2011 – Biocartis today announces that it has been selected as a Technology Pioneer 2012 by the World Economic Forum. Technology Pioneers comprise…
Read More
Biocartis raises €30 million in Series B’ financing round
Press Release. Lausanne, Switzerland - Biocartis SA, a biotech company active in the field of personalized medicine and focused on fast, multiplexed and fully integrated molecular diagnostics based on…
Read More
Biocartis acquires Philips Technology Platform for Automated DNA/RNA Molecular Diagnostic Testing
Press Release. Eindhoven, The Netherlands – Molecular diagnostics company Biocartis and Royal Philips Electronics (NYSE: PHG, AEX: PHI) today announced the signing of an agreement that will result in…
Read More
